Abstract |
Five patients with mild hypertension were given single oral doses of Ro 31-1118 (10,20,40, and 80 mg) and placebo in a randomized, double-blind, within-patient study. Plasma concentrations of Ro 31-1118 and supine, standing, exercise, and post-exercise heart rates and blood pressures were measured before and at regular intervals after drug administration. The pharmacokinetic data were consistent with a one-compartment model with first-order absorption and a variable time lag. Peak plasma concentrations and area under curve were linearly related to dose, whereas time to peak concentration, half-time, clearance and apparent volume of distribution were dose-independent. There was a reduction in exercise and post-exercise heart rate of approximately 10% after 10 mg and 20 mg Ro 31-1118, and of approximately 15% after 40 mg and 80 mg. At all doses standing systolic blood pressure was reduced by approximately 5%. A similar fall was seen in exercise and post-exercise systolic blood pressures. There was no substantial effect of Ro 31-1118 on supine or standing heart rates nor on diastolic blood pressure. No adverse effects were reported. It is concluded that Ro 31-1118 has linear pharmacokinetics over the dose range 10-80 mg, and has a weak antihypertensive effect when administered in single doses to patients with mild hypertension.
|
Authors | M Jamieson, J C Petrie, J Webster, A Miller, R I Harris, R J Francis |
Journal | European journal of clinical pharmacology
(Eur J Clin Pharmacol)
Vol. 29
Issue 4
Pg. 395-9
( 1985)
ISSN: 0031-6970 [Print] Germany |
PMID | 2868899
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Adrenergic beta-Antagonists
- Phenoxypropanolamines
- Propanolamines
- flusoxolol
|
Topics |
- Absorption
- Administration, Oral
- Adrenergic beta-Antagonists
(metabolism, therapeutic use)
- Adult
- Blood Pressure
(drug effects)
- Clinical Trials as Topic
- Double-Blind Method
- Heart Rate
(drug effects)
- Humans
- Hypertension
(drug therapy)
- Kinetics
- Male
- Middle Aged
- Phenoxypropanolamines
- Physical Exertion
- Posture
- Propanolamines
(administration & dosage, metabolism, therapeutic use)
- Random Allocation
- Time Factors
|